June 19, 2017 10:26 am
An exclusive gathering of high profile professionals, the event’s attendee profile ranged from about 90 to 100 clinical trials specialists with more than 12 hours of networking throughout the course of two days.
June 16, 2017 11:42 am
The U.S. Food and Drug Administration (FDA) approved Adamis Pharmaceutical’s EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) for the emergency treatment of allergic reactions, including anaphylaxis.
June 16, 2017 10:17 am
The legislation focuses on manufacturers of diabetes treatments and pharmacy benefits managers.
June 16, 2017 10:23 am
The new trial will enroll approximately 5,000 people with chronic kidney disease—both with and without type 2 diabetes.
June 15, 2017 10:26 am
One of the top life science focused venture capital firms is continuing an ambitious hiring spree.
June 14, 2017 8:00 am
Novo’s insulin product is a once-daily long-acting form of the diabetes treatment.
June 13, 2017 4:21 pm
Ribbon-cutting event included town hall discussion and tour of facility, which helps bioprocessing manufacturers rapidly evaluate single-use technologies.
June 13, 2017 12:23 pm
Canagliflozin (Invokana) significantly reduced the combined risk of cardiovascular death, myocardial infarction, and nonfatal stroke, versus placebo in patients with type 2 diabetes at risk for or with a history of cardiovascular disease.
June 12, 2017 2:38 pm
Two prominent pharmaceutical firms from overseas released promising new findings that could stave off low blood sugar.
June 12, 2017 11:44 am
Flexion Therapeutics, Inc. presented data from a Phase II study which found its lead investigational drug candidate, FX006 (Zilretta) was associated with reduced blood glucose elevation compared with immediate release triamcinolone acetonide in crystalline suspension (TAcs) in patients with Type 2 diabetes and knee osteoarthritis (OA).